On the other hand, 3 cases from the high-risk group (GS6 PCa, PSA > 20 ng/mL) and 14 cases from the intermediate-risk group (GS6 PCa, PSA 10–20 ng/mL) were assessed as not being clinically significant. The gene discussed is KLK3; the disease is posterior cortical atrophy.